46 completed. 46 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Completed 46 |
| Phase 2 | 15 | Completed 15 |
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study - Anemia, Fatigue | Phase 1 | Completed | City of Hope Medical Center | 3 | 2017-09-07 | 2026-10-19 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Selinexor, Ibrutinib, Pharmacological Study - Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Completed | Jennifer Woyach | 34 | 2015-06-09 | 2025-06-10 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | University of California, Davis | 20 | 2014-10-01 | 2019-01-04 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ibrutinib, Lenalidomide - Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2013-04-26 | 2022-09-26 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant allogeneic cytomegalovirus-specific cytotoxic T lymphocytes - Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 1 | 2012-04-01 | 2017-02-15 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Akt Inhibitor MK2206, Bendamustine Hydrochloride, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2011-09-01 | 2017-09-15 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
Showing 20 of 46. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (46) · Lymphoma, Mantle-Cell (29) · Lymphoma, Follicular (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Lymphoma, Large B-Cell, Diffuse (22) · Lymphoma, B-Cell, Marginal Zone (21) · Waldenstrom Macroglobulinemia (19) · Lymphoma, Non-Hodgkin (18) · Burkitt Lymphoma (17) · Hodgkin Disease (17) · Multiple Myeloma (16) · Lymphoma, Large-Cell, Immunoblastic (15) · Leukemia, Prolymphocytic (14) · Lymphoma, Large-Cell, Anaplastic (14) · Lymphoma, T-Cell, Cutaneous (14)
Chronic Disease (46) · Disease Attributes (46) · Hematologic Diseases (46) · Hemic and Lymphatic Diseases (46) · Immune System Diseases (46) · Immunoproliferative Disorders (46) · Leukemia (46) · Leukemia, B-Cell (46) · Leukemia, Lymphoid (46) · Lymphatic Diseases (46) · Lymphoproliferative Disorders (46) · Neoplasms by Histologic Type (46) · Pathologic Processes (46) · Pathological Conditions, Signs and Symptoms (46) · Neoplasms (45)
fludarabine phosphate (9) · Mycophenolic Acid (6) · Rituximab (6) · Cyclosporine (5) · Whole-Body Irradiation (5) · Cyclophosphamide (4) · Lenalidomide (4) · Peripheral Blood Stem Cell Transplantation (4) · Bendamustine Hydrochloride (3) · alvocidib (3) · Bortezomib (2) · Cyclosporins (2) · Everolimus (2) · Flow Cytometry (2) · MK 2206 (2)
National Cancer Institute (NCI) (22) · Fred Hutchinson Cancer Center (9) · City of Hope Medical Center (2) · Mayo Clinic (2) · Alexey Danilov, MD (1) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · Chinese PLA General Hospital (1) · Jennifer Woyach (1) · Joseph Tuscano (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Ohio State University Comprehensive Cancer Center (1) · Robert Lowsky (1) · University of California, Davis (1) · University of Pennsylvania (1)
United States (45) · Germany (3) · Italy (3) · Canada (2) · China (1)
Brenda Sandmaier (3) · John Byrd (3) · Brenda Cooper (2) · David Maloney (2) · Jennifer Woyach, MD (2) · Kristie Blum (2) · Maryam Fouladi (2) · Shaji Kumar (2) · Amir Mortazavi, MD (1) · Brian Till (1) · Cameron Turtle (1) · Colleen Delaney (1) · Craig Okada, M.D. (1) · Daniel A Pollyea (1) · Ewa Carrier (1)
PMID 32499241, PMID 34515338, PMID 17679729, PMID 18974373, PMID 19679883, PMID 19826119, PMID 21072184, PMID 22259028, PMID 22289993, PMID 22308288, PMID 23887852, PMID 24474568, PMID 24990615, PMID 25317870, PMID 26853648, PMID 26943915, PMID 27111235, PMID 28270022, PMID 28314788, PMID 29038338, PMID 29572391, PMID 30562587, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31076448, PMID 31617432, PMID 31648294, PMID 31815579, PMID 32967009, PMID 33492438, PMID 34196037, PMID 34666344, PMID 37774014, PMID 39333103, PMID 39863139, PMID 41804087, PMID 42389828
U01CA076576 (8), P30CA015704 (6), P30CA016058 (5), U01CA062502 (3), U01CA062505 (3), P01CA018029 (2), P01CA078902 (2), P50CA140158 (2), R01CA136551 (2), U01CA069912 (2), U01CA097452 (2), UM1CA186712 (2), UM1CA186717 (2), N01CM00070 (1), N01CM62207 (1)